机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.临床科室耳鼻咽喉-头颈外科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.研究所耳鼻咽喉科研究所首都医科大学附属北京同仁医院首都医科大学附属同仁医院[3]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.[4]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.临床科室变态反应科首都医科大学附属北京同仁医院首都医科大学附属同仁医院
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease. High proportions of patients with CRSwNP characterized by type 2 inflammation fail to gain adequate control with conventional treatment. The application of biologics in clinics and assessments of novel biologics in clinical trials are blooming in expectations to fulfill the unmet medical needs of patients with CRSwNP with type 2 inflammation.After an extensive search of PubMed, Medline, and EMBASE for the most recent evidence, we thoroughly summarize current advances in biological therapies for treating patients with CRSwNP.In recent years, biological therapy has been in the spotlight in clinical studies on CRSwNP. Biologics have proven to be efficacious in reducing nasal polyp size, alleviating CRSwNP-related symptoms, improving quality of life, and reducing the need for systemic corticosteroids or endoscopic sinus surgery for nasal polyps. The considerable efficacy and safety profile of biologics has offered patients with refractory CRSwNP another treatment option. However, some concerns remain to be addressed. Aspects such as the position of biological therapy in the management of CRSwNP, traits of patients suitable for certain biologics, etc. necessitate efforts to elucidate these unknowns in order to provide patients with tailored therapy.
基金：
National Key R&D Program of
China [2023YFC2410200]; the National Natural Science Foundation of
China [82025010, 82471135, and 82171108]; Changjiang Scholars and
Innovative Research Team [IRT13082]; Beijing Municipal Science and
Technology Project [Z221100007422009 and Z211100002921057];
Capital’s Funds for Health Improvement and Research [CFH2022-1-1091];
Beijing Municipal Administration of Hospitals’ Yangfan plan [YGLX202303];
Talent program of Capital Medical University [A2306]; Special Funds for
the Construction of High-level Public Health Technical Talents
[Lingjunrencai-02–09 and backbone of academic research-03–03]; and
Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes [JYY2021–2 and JYY2023–1]
第一作者机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.[2]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.[3]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.[2]Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China.[3]Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, China.[4]Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China.
推荐引用方式(GB/T 7714)：
Jin Zeyi,Yan Bing,Zhang Luo,et al.Biological therapy in chronic rhinosinusitis with nasal polyps[J].Expert Review Of Clinical Immunology.2025,1-21.doi:10.1080/1744666X.2025.2459929.
APA：
Jin Zeyi,Yan Bing,Zhang Luo&Wang Chengshuo.(2025).Biological therapy in chronic rhinosinusitis with nasal polyps.Expert Review Of Clinical Immunology,,
MLA：
Jin Zeyi,et al."Biological therapy in chronic rhinosinusitis with nasal polyps".Expert Review Of Clinical Immunology .(2025):1-21
：